Mometasone furoate is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo. Mometasone furoate exhibits high potency with greater anti-inflammatory activity and a longer duration of action than betamethasone. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity[3]. Breast cancer patients receiving MF (Mometasone Furoate) during PMRT (postmastectomy radiation) experienced significantly reduced rates of moist desquamation in comparison with a control cream[4].
Mometasone furoate/糠酸莫美他松 细胞实验
Cell Line
Concentration
Treated Time
Description
References
U2OS
20.92 µM (IC50), 16.909 µM (IC25)
48 hours
MF significantly inhibited the proliferation and metastasis of U2OS cells and induced S phase arrest and apoptosis.
J Bone Oncol. 2024 Jun 29;47:100618.
MG63
36.86 µM (IC50), 26.423 µM (IC25)
48 hours
MF significantly inhibited the proliferation and metastasis of MG63 cells and induced S phase arrest and apoptosis.
J Bone Oncol. 2024 Jun 29;47:100618.
MNNG-HOS
30.26 µM (IC50), 25.974 µM (IC25)
48 hours
MF significantly inhibited the proliferation and metastasis of MNNG-HOS cells and induced S phase arrest and apoptosis.
J Bone Oncol. 2024 Jun 29;47:100618.
DPPC:POPC:POPG:CHOL (60:20:10:10) mixed monolayer
0.72% w/w to 14.84% w/w
To investigate the effect of Mometasone furoate on lung surfactant monolayers. Results showed that drug concentrations below 4.18% w/w minimally affect the physicochemical characteristics of the monolayer, while higher concentrations lead to monolayer collapse.
搜索
